About: SARS-Coronavirus-2 Nsp13 Possesses NTPase and RNA Helicase Activities That Can Be Inhibited by Bismuth Salts

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: SARS-Coronavirus-2 Nsp13 Possesses NTPase and RNA Helicase Activities That Can Be Inhibited by Bismuth Salts Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	SARS-Coronavirus-2 Nsp13 Possesses NTPase and RNA Helicase Activities That Can Be Inhibited by Bismuth Salts
Creator	Shu, Ting Mu, Jingfang Wu, • Zhou, • Wang, Ruibing Huang, Muhan Ren, Yujie Zhang, Ding-Yu Zhang, Xueyi Yang Qiu, • Han, •
Source	Medline; PMC
abstract	The ongoing outbreak of Coronavirus Disease 2019 (COVID-19) has become a global public health emergency. SARS-coronavirus-2 (SARS-CoV-2), the causative pathogen of COVID-19, is a positive-sense single-stranded RNA virus belonging to the family Coronaviridae. For RNA viruses, virus-encoded RNA helicases have long been recognized to play pivotal roles during viral life cycles by facilitating the correct folding and replication of viral RNAs. Here, our studies show that SARS-CoV-2-encoded nonstructural protein 13 (nsp13) possesses the nucleoside triphosphate hydrolase (NTPase) and RNA helicase activities that can hydrolyze all types of NTPs and unwind RNA helices dependently of the presence of NTP, and further characterize the biochemical characteristics of these two enzymatic activities associated with SARS-CoV-2 nsp13. Moreover, we found that some bismuth salts could effectively inhibit both the NTPase and RNA helicase activities of SARS-CoV-2 nsp13 in a dose-dependent manner. Thus, our findings demonstrate the NTPase and helicase activities of SARS-CoV-2 nsp13, which may play an important role in SARS-CoV-2 replication and serve as a target for antivirals. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s12250-020-00242-1) contains supplementary material, which is available to authorized users.
has issue date	2020-06-04(xsd:dateTime)
bibo:doi	10.1007/s12250-020-00242-1
bibo:pmid	32500504
has license	no-cc
sha1sum (hex)	5f6b864972de6f6797dc83a45d4aafbeeae5e9aa
schema:url	https://doi.org/10.1007/s12250-020-00242-1
resource representing a document's title	SARS-Coronavirus-2 Nsp13 Possesses NTPase and RNA Helicase Activities That Can Be Inhibited by Bismuth Salts
has PubMed Central identifier	PMC7271831
has PubMed identifier	32500504
schema:publication	Virol Sin
resource representing a document's body	covid:5f6b864972de6f6797dc83a45d4aafbeeae5e9aa#body_text
is schema:about of	named entity 'For' named entity 'positive-sense single-stranded RNA virus' named entity 'RNA' named entity 'RNAs' named entity 'HELICES' named entity 'GLOBAL' named entity 'SARS-COV-2' named entity 'POSSESSES' named entity 'PATHOGEN' named entity 'REPLICATION' named entity 'replication' named entity 'global public health' named entity 'target' named entity 'Coronavirus' named entity 'SARS-CoV-2' named entity 'possesses' named entity 'activities' named entity 'SARS-CoV-2' named entity 'nucleoside triphosphate' named entity 'NTP' named entity 'SARS-CoV-2' named entity 'RNA' named entity 'enzymatic activities' named entity 'biochemical' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'pathogen' named entity 'NTP' named entity 'public health emergency' named entity 'RNA helicase' named entity 'NTPase' named entity 'NTPase' named entity 'RNA Helicase' named entity 'SARS' named entity 'Salts' named entity 'NTPase' named entity 'mmol' named entity 'NTPase' named entity 'ORFs' named entity 'hydrolyzing ATP' named entity 'SARS-CoV-2' named entity 'flavonoids' named entity 'hydroxyethyl' named entity 'restriction sites' named entity 'SARS-CoV-2' named entity 'dsRNA' named entity 'antivirals' named entity 'centrifugation' named entity 'SARS-CoV' named entity 'E. coli' named entity 'negative control' named entity 'SARS-CoV-2' named entity 'Zinc-binding' named entity 'SARS-CoV-2' named entity 'GTP' named entity 'bismuth' named entity 'coronaviruses' named entity 'primers' named entity 'RBC' named entity 'SARS-CoV-2' named entity 'MBP' named entity 'RNA helicase' named entity 'electrophoresis' named entity 'testes' named entity 'SARS-CoV-2' named entity 'RNA' named entity 'nidoviruses' named entity 'bismuth' named entity 'MBP' named entity 'Changzhou' named entity 'replicase'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software